Development of CD46 targeted alpha theranostics in prostate cancer using <sup>134</sup>Ce/<sup>225</sup>Ac-Macropa-PEG<sub>4</sub>-YS5
Kondapa Naidu Bobba(University of California, San Francisco), Robert R. Flavell(University of California, San Francisco)
Cited by 27
Related Papers
Treatment of prostate cancer with CD46 targeted <sup>225</sup> Ac alpha particle radioimmunotherapy
|bioRxiv (Cold Spring Harbor Laboratory)|2022|0